Why the name is an invitation.

Nathan Wooten, PharmD

Founder

Nathan has spent nearly seventeen years in hospital pharmacy, the last decade of it in leadership, and has been directly responsible for a 340B program for most of that time — first as assistant director at Hamilton Medical Center, where he ran the inpatient, retail and long-term care pharmacies, then as director at a second health system. He holds the Apexus Advanced 340B Operations Certificate and a Doctor of Pharmacy from the University of Georgia, where he graduated magna cum laude.

The retail half of that matters more than it sounds. Retail dispensing and contract pharmacy are where a large share of 340B savings and a large share of 340B exposure both sit — and comparatively few people advising on either have ever run one. He has worked extensively with contract pharmacy arrangements since.

Those programs sat under different covered entity types, and the rules genuinely move with the type. The GPO prohibition binds a disproportionate share hospital and not a sole community hospital; the orphan drug exclusion runs the other way. He has run both, and consults across rural referral centers, Ryan White programs and FQHCs — designing programs, and bringing them into compliance while raising what they return. Not a compliance project followed one day by an optimization project: the pass that closes the gaps is the pass that finds the money. It is the difference between having seen 340B once and having seen it behave differently under five different sets of rules.

The reason this practice exists is straightforward: he has run these programs from inside the covered entity, and he has been on the receiving end of the audit. Within three weeks of stepping into a director role he completed and had accepted a HRSA corrective action plan, then built the 340B oversight committee that kept the program compliant afterward — while a GPO and wholesaler conversion, an automated dispensing implementation, and an Epic go-live were all in flight at the same time.

Running a 340B program well is, more than anything, a governance problem. He implemented the 340B oversight committee at one health system and co-chaired it with the CFO, and has served on Pharmacy and Therapeutics, Compliance, Quality, Diversion Oversight, and Chemotherapy and Infusion Quality committees. Those rooms are where formulary decisions, compliance findings and purchasing strategy actually meet — and where a 340B program is either coordinated or quietly working against itself.

It also means he has spent as much time at the organization's committee tables as in the pharmacy. Conversations with a compliance officer, a CMO or a CFO are familiar ground rather than a translation exercise.

He has been through the HRSA audit process more than once, including a follow-up audit years later. HRSA publishes its audit results; he will walk through them with anyone who asks. Joint Commission surveys, state board of pharmacy inspections and annual external audits have run the same way since. Surveys don't come back empty — but nothing came back that put the organization at risk or required a corrective action plan, and the pharmacy items were typically a policy worth writing down, or something that belonged to facilities rather than to the department.

That record is the foundation, not the point of the work. What he is actually known for is finding money and workable solutions where other people had stopped looking: rebuilding a pharmacy charge master; spotting a pharmacy benefit opportunity nobody had priced and co-leading the negotiation; co-developing inventory optimization software with a manufacturer; converting to ready-to-use presentations that cut drug waste and nursing time and freed cabinet capacity at the same time.

The dollar figures behind those are not published here. They were not incidental.

Little of that list is 340B work. The charge master, the pharmacy benefit negotiation, the inventory software, the ready-to-use conversion — none of them sit inside the program, and every one of them changed what the program was worth. The contract side is the same story: he has chaired a pharmacy aggregation group of eight hospitals — the table where purchasing leverage is pooled, well outside anything the 340B program controls.

That is why the practice does not stop at the edge of the program. 340B is usually where the conversation starts, because it is the piece with a name and an audit attached. In his own career it was almost never where the work ended.

One disclosure, because this is a field where it matters. He is a co-owner of N2 Pharmacy Analytics, a healthcare software and analytics company. Where one of its tools would genuinely fit an engagement, that interest is put in front of the client before the tool is ever recommended — and the recommendation survives being refused.

That history is the whole methodology. Consultants who have never sat across from an auditor tend to produce findings that don't survive one — and consultants who have only ever worked the program tend to miss the decisions that determine what it is worth.